Fig. 1: Characteristics of second malignant neoplasms (SMN) in the 75 included patients from trial AIEOP-BFM ALL 2000. | Leukemia

Fig. 1: Characteristics of second malignant neoplasms (SMN) in the 75 included patients from trial AIEOP-BFM ALL 2000.

From: Germline variants in patients developing second malignant neoplasms after therapy for pediatric acute lymphoblastic leukemia—a case-control study

Fig. 1

A Entities of SMN; (B) time from diagnosis of the acute lymphoblastic leukemia (ALL) to SMN development; median time to SMN was 3.36 ± 3.98 (0.57–13.37) years for patients with hematologic SMN, 8.61 ± 1.69 (5.12–11.43) years for patients with second brain tumors, and 8.45 ± 4.04 (1.92–15.91) years for patients with other second solid tumors. Black-bordered dots represent patients with a (likely) pathogenic variant (LP/P) in one of the candidate genes; the adjacent numbers correspond to the respective patient IDs (for further details, compare Table 1 and Supplementary Tables 3, 4). Abbreviations: MDS myelodysplastic syndrome, AML acute myeloid leukemia, CML chronic myeloid leukemia, PTLD post-transplant lymphoproliferative disorder.

Back to article page